Leerink Partners Issues Positive Forecast for Zymeworks (NASDAQ:ZYME) Stock Price

Zymeworks (NASDAQ:ZYME) had its price objective increased by Leerink Partners from $52.00 to $58.00 in a research note issued to investors on Tuesday morning,Benzinga reports. The brokerage currently has an outperform rating on the stock.

ZYME has been the topic of a number of other reports. Truist Financial began coverage on shares of Zymeworks in a research note on Wednesday, December 17th. They issued a “buy” rating and a $40.00 price target on the stock. HC Wainwright increased their target price on Zymeworks from $26.00 to $32.00 and gave the company a “buy” rating in a report on Tuesday, November 18th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zymeworks in a research note on Wednesday, January 21st. Wall Street Zen cut Zymeworks from a “buy” rating to a “hold” rating in a research report on Saturday, November 8th. Finally, Wells Fargo & Company upgraded Zymeworks from an “equal weight” rating to an “overweight” rating and raised their price objective for the company from $25.00 to $33.00 in a report on Friday, December 12th. Two analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $35.70.

Zymeworks Stock Performance

Zymeworks stock opened at $24.45 on Tuesday. The company’s fifty day moving average price is $23.85 and its 200 day moving average price is $20.95. Zymeworks has a 1 year low of $9.03 and a 1 year high of $28.49. The stock has a market capitalization of $1.83 billion, a P/E ratio of -22.64 and a beta of 1.23.

Zymeworks (NASDAQ:ZYME) last posted its quarterly earnings data on Monday, March 2nd. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.20). Zymeworks had a negative net margin of 76.56% and a negative return on equity of 24.85%. The company had revenue of $2.52 million for the quarter, compared to analysts’ expectations of $21.78 million. During the same period in the previous year, the business earned ($0.31) earnings per share. The business’s revenue for the quarter was down 91.9% on a year-over-year basis.

Insider Buying and Selling

In other Zymeworks news, COO Mark Hollywood sold 6,120 shares of the firm’s stock in a transaction on Monday, January 12th. The stock was sold at an average price of $22.67, for a total value of $138,740.40. Following the completion of the sale, the chief operating officer directly owned 132,913 shares of the company’s stock, valued at $3,013,137.71. This trade represents a 4.40% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Kenneth Galbraith sold 54,343 shares of Zymeworks stock in a transaction on Monday, January 5th. The stock was sold at an average price of $25.10, for a total value of $1,364,009.30. Following the transaction, the chief executive officer owned 158,286 shares in the company, valued at approximately $3,972,978.60. This represents a 25.56% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 187,933 shares of company stock worth $4,673,716. 33.51% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Zymeworks

Hedge funds and other institutional investors have recently bought and sold shares of the company. AQR Capital Management LLC raised its stake in Zymeworks by 86.0% during the first quarter. AQR Capital Management LLC now owns 48,485 shares of the company’s stock worth $577,000 after purchasing an additional 22,411 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Zymeworks by 4.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 32,385 shares of the company’s stock valued at $386,000 after buying an additional 1,427 shares during the period. Jane Street Group LLC increased its holdings in shares of Zymeworks by 487.0% during the 1st quarter. Jane Street Group LLC now owns 135,763 shares of the company’s stock worth $1,617,000 after buying an additional 112,636 shares during the last quarter. Bank of Montreal Can increased its holdings in shares of Zymeworks by 6.7% during the 2nd quarter. Bank of Montreal Can now owns 27,642 shares of the company’s stock worth $347,000 after buying an additional 1,730 shares during the last quarter. Finally, Campbell & CO Investment Adviser LLC purchased a new stake in shares of Zymeworks during the 2nd quarter valued at approximately $188,000. 92.89% of the stock is currently owned by institutional investors and hedge funds.

Key Zymeworks News

Here are the key news stories impacting Zymeworks this week:

• Positive Sentiment: Wall Street upgrades — Stifel raised its price target to $47 (buy) and Leerink Partners raised its target to $58 (outperform), both signaling strong analyst conviction and meaningful upside vs. the current price. Benzinga (Stifel) Benzinga (Leerink)
• Positive Sentiment: $250M non‑recourse royalty‑backed financing with Royalty Pharma provides immediate, non‑dilutive capital while preserving most future Ziihera royalties — improves flexibility to continue buybacks and pursue strategic moves. GlobeNewswire: Royalty‑Backed Financing
• Positive Sentiment: Commercial and milestone upside for Ziihera — partner Jazz is completing a supplemental BLA for first‑line HER2+ GEA (expected Q1 2026) with a potential 2H‑2026 launch; Zymeworks is eligible for up to ~$440M in GEA‑related milestones plus future royalties and further milestone pools. This underpins the company’s revenue runway and valuation re‑rating. GlobeNewswire: Corporate Update
• Positive Sentiment: Share‑repurchase execution — company has repurchased ~$62.5M under the authorized program to date; combined with the Royalty Pharma funding this supports near‑term buybacks and EPS accretion expectations. GlobeNewswire: Repurchase Details
• Neutral Sentiment: Earnings call & transcripts published — management reviewed strategy shift toward royalty/asset aggregation, R&D priorities and three‑year expense discipline; transcripts and presentations are available for detail (useful for modeling, but not new headlines). Yahoo Finance: Q4 2025 Earnings Call Summary
• Negative Sentiment: Q4 results missed expectations — reported EPS of $(0.55) vs. consensus $(0.35) and Q4 revenue of $2.52M (down sharply year‑over‑year). The weak quarterly revenue and continued GAAP losses are near‑term headwinds and warrant conservative near‑term models until royalties and milestone receipts ramp. Zacks: Q4 Loss & Revenue Miss

About Zymeworks

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. The company specializes in engineered antibody and protein therapeutics designed to address a range of unmet medical needs in oncology and other serious diseases. Through its proprietary platforms, Zymeworks aims to create novel bispecific and multispecific molecules that can simultaneously engage multiple targets and recruit immune effector functions to enhance potency and specificity.

At the core of Zymeworks’ innovation is its Azymetric™ bispecific antibody platform, which enables the design of asymmetrical bispecific antibodies with controlled assembly and high stability.